COMMUNIQUÉS West-GlobeNewswire

Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call

28/02/2025 - 14:00

DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView ® System, which received Breakthrough Device Designation from the U.S. Food and [...]

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

28/02/2025 - 14:00

-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47 phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson’s Disease; expect to file IND and/or CTA in 1H 2026 -- -- [...]

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

28/02/2025 - 14:00

BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]

Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center

28/02/2025 - 14:00

Premier 735-Bed Healthcare Facility Implements ezBVA Lab Service to Enhance Cardiovascular Outpatient Care Oak Ridge, TN, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in [...]

Alignment Healthcare to Present at the Leerink Global Healthcare Conference and KeyBanc Capital Markets Healthcare Forum

28/02/2025 - 14:00

ORANGE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the following conferences: Leerink Global Healthcare Conference on Tuesday, March 11, [...]

Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025

28/02/2025 - 14:00

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of [...]

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

28/02/2025 - 14:00

REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]

Johnson & Johnson’s DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility

28/02/2025 - 14:01

If approved, daratumumab will be the only anti-CD38 available for all patient types across newly diagnosed multiple myeloma, cementing daratumumab as a foundational therapy in the frontline setting. Recommendation [...]

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

28/02/2025 - 14:05

ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the [...]

CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

28/02/2025 - 14:15

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study 1,2 DLBCL—an aggressive disease with a high risk of progression—remains an area of high unmet need, especially [...]

Safety Shot, Inc. Appoints CORE IR & PR for Investor Relations, Shareholder Communications and Public Relations Services

28/02/2025 - 14:30

CORE IR & PR to support strategic communications in conjunction with corporate development and commercial activities SCOTTSDALE, Ariz., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) ("Safety [...]

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval

28/02/2025 - 14:30

HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical Trials HOUSTON, TX, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep [...]

Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company’s Continuous Glucose Monitoring Technology

28/02/2025 - 14:30

DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable [...]

Noom Expands into Hormone Replacement Therapy to Support Women’s Health and Well-being

28/02/2025 - 14:37

Noom + HRT Rx blends Noom’s proven behavior change program with HRT medication to achieve whole-person health The new offering builds on the rapid growth of the company’s medically assisted weightloss franchise, which [...]

TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis

28/02/2025 - 14:43

Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1 Beerse, Belgium (28 February 2025) – Johnson & Johnson today announced that the Committee for Medicinal Products for [...]

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

28/02/2025 - 14:45

Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains OCALA, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today [...]

Ultimovacs ASA: Approval and publication of prospectus

28/02/2025 - 14:45

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. [...]

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

28/02/2025 - 15:00

JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all [...]

WORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.

28/02/2025 - 15:00

Hangzhou, China, Feb. 28, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices, through its subsidiary, Work (Hangzhou) Medical [...]